9:24 AM
 | 
Jul 13, 2018
 |  BC Extra  |  Clinical News

Advaxis rises after FDA lifts clinical hold

Advaxis Inc. (NASDAQ:ADXS) jumped $0.12 (10%) to $1.34 Friday after it said FDA lifted a clinical hold on a Phase I/II combination study that includes the company's axalimogene filolisbac (ADXS11-001).

The trial is evaluating the therapy in combination with PD-L1 inhibitor Imfinzi durvalumab to treat advanced, recurrent or refractory cervical cancer and...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >